Sophiris Bio Inc.
https://www.sophirisbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sophiris Bio Inc.
Phathom Voquezna Expansion Strategy Poised To Deliver In GERD
The acid reducer was approved by the US FDA for a substantially larger indication in non-erosive gastroesophageal reflux disease but will have to prove itself commercially against PPIs.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Finance Watch: Two New VC Funds Bring $365m For Start-Ups
Private Company Edition: Amplitude Ventures raised $192m for its second fund, while XGEN Venture debuted with €160m ($173.4m). Also, hub-and-spoke biopharma operator CinRx added $73m, Adcendo extended its series A round to €98m ($106.2m) and Grey Wolf raised $50m.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Protox Therapeutics, Inc.
- Sophiris Bio, Inc.
- Sophiris Bio Corp., Sophiris Bio Holding Corp.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice